help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on July 19, 2007
Endocrinology, doi:10.1210/en.2007-0208
A more recent version of this article appeared on October 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/10/4676    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, M. B.
Right arrow Articles by Stoica, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, M. B.
Right arrow Articles by Stoica, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL

Submitted on February 13, 2007
Accepted on July 9, 2007

EFFECTS OF TOBACCO SMOKE CONDENSATE ON ESTROGEN RECEPTOR-{alpha} GENE EXPRESSION AND ACTIVITY

Mary Beth Martin, Ronald Reiter, Michael Johnson, Mansi S. Shah, Mary C. Iann, Baljit Singh, Julie Kate Richards, Antai Wang, and Adriana Stoica*

Department of Oncology, Georgetown University, Washington DC 20007, Box 571469; School of Nursing and Health Studies, Georgetown University, Washington DC 20007; Department of Biostatistics, Bioinformatics, and Biomathematics

* To whom correspondence should be addressed. E-mail: stoicaa{at}georgetown.edu.

Metalloestrogens are a new class of potent environmental estrogens. This study investigates whether tobacco smoke condensate (TSC), which contains metals and metalloids, elicits estrogen like effects at environmentally relevant doses. Treatment of human breast cancer cells, MCF-7, with 40 µg/ml of TSC resulted in a 2.5-fold stimulation of cell growth. TSC decreased the concentration of ER-{alpha} protein and mRNA (63% and 62%), and increased the expression of the estrogen regulated genes, progesterone receptor (PR) and pS2 (5- and 2-fold). Additionally, TSC activated ER-{alpha} in COS-1 or CHO cells transiently transfected with wild type ER-{alpha} and an ERE-CAT or an ERE-luciferase reporter gene (11- and 6-fold). TSC also activated a chimeric receptor (GAL-ER) containing the hormone binding domain of ER-{alpha} (3.5-fold). TSC blocked the binding of estradiol to the receptor without altering the affinity of estradiol (Kd = 2.2-6.8 x 10-10 M). Transfection assays with ER-{alpha} mutants identified C381, C447, H524, N532, E523, and D538 in the hormone binding domain as important for activation by TSC. In ovariectomized rats, low doses of TSC (10 or 20 mg/kg body weight) increased uterine wet weight (1.7- and 2.1-fold) and induced the expression of PR and complement C3 in the uterus (2- and 26-fold) and mammary gland (4.4- and 15-fold). Both the in vitro and in vivo TSC effects were blocked by the antiestrogen ICI 182,780 suggesting the involvement of ER. Collectively, these results provide strong evidence that low doses of TSC, acting through the hormone binding domain, exert estrogen like effects in cell culture and in animals.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society